Skip to main content
Top
Published in: Pediatric Drugs 6/2014

01-12-2014 | Therapy in Practice

Pharmacological Treatment of Chronic Non-Cancer Pain in Pediatric Patients

Authors: Eapen Mathew, Eugene Kim, Kenneth R. Goldschneider

Published in: Pediatric Drugs | Issue 6/2014

Login to get access

Abstract

Chronic pain in children and young adults occurs frequently and contributes to early disability as well as personal and familial distress. A biopsychosocial approach to evaluation and treatment is recommended. Within this approach, there is a role for pharmacologic intervention. A variety of medications are used for chronic pain conditions in pediatric patients. Medication classes include anticonvulsants, muscle relaxants, antidepressants, opioids, local anesthetics, and anti-inflammatory drugs. Data is sparse, and most medications are used without condition-specific approval by national regulatory agencies such as the Food and Drug Administration in the US and the European Medicines Agency. In the absence of evidence on which to base practice, optimal drug therapy decisions rest on understanding proposed mechanisms of pain conditions, extrapolation from adult data—when such exists, and empirical and experiential knowledge. Drug delivery systems have evolved, and practitioners have to decide amongst not only medication classes, but also routes of delivery. Opioids are not recommended for use by non-pain specialists for the treatment of pediatric chronic pain, and even then the issues are more complex than can be addressed here. This article reviews the major medications used for pediatric chronic pain conditions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Perquin CW, Hazebroek-Kampschreur AA, Hunfeld JA, Bohnen AM, van Suijlekom-Smit LW, Passchier J, et al. Pain in children and adolescents: a common experience. Pain. 2000;87(1):51–8.PubMed Perquin CW, Hazebroek-Kampschreur AA, Hunfeld JA, Bohnen AM, van Suijlekom-Smit LW, Passchier J, et al. Pain in children and adolescents: a common experience. Pain. 2000;87(1):51–8.PubMed
2.
go back to reference Roth-Isigkeit A, Thyen U, Raspe HH, Stoven H, Schmucker P. Reports of pain among German children and adolescents: an epidemiological study. Acta Paediatr. 2004;93(2):258–63.PubMed Roth-Isigkeit A, Thyen U, Raspe HH, Stoven H, Schmucker P. Reports of pain among German children and adolescents: an epidemiological study. Acta Paediatr. 2004;93(2):258–63.PubMed
3.
go back to reference Roth-Isigkeit A, Thyen U, Stoven H, Schwarzenberger J, Schmucker P. Pain among children and adolescents: restrictions in daily living and triggering factors. Pediatrics. 2005;115(2):e152–62. doi:10.1542/peds.2004-0682.PubMed Roth-Isigkeit A, Thyen U, Stoven H, Schwarzenberger J, Schmucker P. Pain among children and adolescents: restrictions in daily living and triggering factors. Pediatrics. 2005;115(2):e152–62. doi:10.​1542/​peds.​2004-0682.PubMed
4.
go back to reference Gregoire MC, Finley GA. Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Res Manag. 2013;18(1):47–50.PubMedCentralPubMed Gregoire MC, Finley GA. Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Res Manag. 2013;18(1):47–50.PubMedCentralPubMed
5.
9.
go back to reference Smith AE, McMullen K, Jensen MP, Carter GT, Molton IR. Symptom burden in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil. 2013;93(5):387–95. doi:10.1097/PHM.0000000000000032. Smith AE, McMullen K, Jensen MP, Carter GT, Molton IR. Symptom burden in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil. 2013;93(5):387–95. doi:10.​1097/​PHM.​0000000000000032​.
12.
go back to reference Goldschneider K. What to Do When There is Nothing to Do. In: Walco GA, Goldschneider K, editors. Pain in children: a practical guide for primary care. Totowa: Humana; 2008. p. 265–9. Goldschneider K. What to Do When There is Nothing to Do. In: Walco GA, Goldschneider K, editors. Pain in children: a practical guide for primary care. Totowa: Humana; 2008. p. 265–9.
14.
go back to reference Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622–30. doi:10.1001/jama.2013.282533.PubMed Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622–30. doi:10.​1001/​jama.​2013.​282533.PubMed
16.
go back to reference Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G. Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev. 2011;(7):CD008013. doi:10.1002/14651858.CD008013.pub2. Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G. Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev. 2011;(7):CD008013. doi:10.​1002/​14651858.​CD008013.​pub2.
18.
go back to reference Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147–59. doi:10.1016/j.jpain.2008.10.007.PubMed Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147–59. doi:10.​1016/​j.​jpain.​2008.​10.​007.PubMed
19.
go back to reference Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics. 2005;116(2):e295–302. doi:10.1542/peds.2004-2742.PubMed Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics. 2005;116(2):e295–302. doi:10.​1542/​peds.​2004-2742.PubMed
21.
go back to reference Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109(1):109–15.PubMed Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109(1):109–15.PubMed
23.
go back to reference Vora SS, Bengtson CE, Syverson GD, Nocton JJ. An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review. Pediatr Rheumatol Online J. 2010;8:11. doi:10.1186/1546-0096-8-11.PubMedCentralPubMed Vora SS, Bengtson CE, Syverson GD, Nocton JJ. An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review. Pediatr Rheumatol Online J. 2010;8:11. doi:10.​1186/​1546-0096-8-11.PubMedCentralPubMed
24.
go back to reference Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010;105(6):1437–43. doi:10.1038/ajg.2009.758.PubMed Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010;105(6):1437–43. doi:10.​1038/​ajg.​2009.​758.PubMed
25.
go back to reference Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009;36(1):174–82. doi:10.3899/jrheum.080073.PubMed Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009;36(1):174–82. doi:10.​3899/​jrheum.​080073.PubMed
26.
go back to reference Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthr Rheum. 2005;52(2):563–72. doi:10.1002/art.20860. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthr Rheum. 2005;52(2):563–72. doi:10.​1002/​art.​20860.
27.
go back to reference Krishnaswami S, Hutmacher MM, Robbins JL, Bello A, West C, Bloom BJ. Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2012;52(8):1134–49. doi:10.1177/0091270011412184.PubMed Krishnaswami S, Hutmacher MM, Robbins JL, Bello A, West C, Bloom BJ. Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2012;52(8):1134–49. doi:10.​1177/​0091270011412184​.PubMed
29.
go back to reference American Academy of Pediatrics. Committee on D. Acetaminophen toxicity in children. Pediatrics. 2001;108(4):1020–4. American Academy of Pediatrics. Committee on D. Acetaminophen toxicity in children. Pediatrics. 2001;108(4):1020–4.
30.
go back to reference Berde CB, Walco GA, Krane EJ, Anand KJ, Aranda JV, Craig KD, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129(2):354–64. doi:10.1542/peds.2010-3591.PubMed Berde CB, Walco GA, Krane EJ, Anand KJ, Aranda JV, Craig KD, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129(2):354–64. doi:10.​1542/​peds.​2010-3591.PubMed
32.
go back to reference Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2–guidance. Pain Physician. 2012;15(3 Suppl):S67–116.PubMed Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2–guidance. Pain Physician. 2012;15(3 Suppl):S67–116.PubMed
33.
go back to reference Schechter NL, Berrien FB, Katz SM. The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: a preliminary report. J Pain Symptom Manage. 1988;3(2):109–13.PubMed Schechter NL, Berrien FB, Katz SM. The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: a preliminary report. J Pain Symptom Manage. 1988;3(2):109–13.PubMed
34.
go back to reference Dampier CD, Smith WR, Wager CG, Kim HY, Bell MC, Miller ST, et al. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013;10(2):319–31. doi:10.1177/1740774513475850.PubMed Dampier CD, Smith WR, Wager CG, Kim HY, Bell MC, Miller ST, et al. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013;10(2):319–31. doi:10.​1177/​1740774513475850​.PubMed
35.
36.
go back to reference Beiter JL Jr, Simon HK, Chambliss CR, Adamkiewicz T, Sullivan K. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med. 2001;155(4):496–500.PubMed Beiter JL Jr, Simon HK, Chambliss CR, Adamkiewicz T, Sullivan K. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med. 2001;155(4):496–500.PubMed
37.
go back to reference Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332–42. doi:10.1542/peds.2008-0441.PubMed Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332–42. doi:10.​1542/​peds.​2008-0441.PubMed
38.
go back to reference Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–22. doi:10.1056/NEJM199505183322001.PubMed Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–22. doi:10.​1056/​NEJM199505183322​001.PubMed
39.
go back to reference Rose JB, Finkel JC, Arquedas-Mohs A, Himelstein BP, Schreiner M, Medve RA. Oral tramadol for the treatment of pain of 7–30 days’ duration in children. Anesth Analg. 2003;96(1):78–81 (table of contents)PubMed Rose JB, Finkel JC, Arquedas-Mohs A, Himelstein BP, Schreiner M, Medve RA. Oral tramadol for the treatment of pain of 7–30 days’ duration in children. Anesth Analg. 2003;96(1):78–81 (table of contents)PubMed
40.
go back to reference Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27–40.PubMed Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27–40.PubMed
42.
go back to reference Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Physician. 2013;16(3):E237–46.PubMed Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Physician. 2013;16(3):E237–46.PubMed
43.
go back to reference Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–82. doi:10.1038/clpt.2013.254.PubMedCentralPubMed Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–82. doi:10.​1038/​clpt.​2013.​254.PubMedCentralPubMed
46.
go back to reference Johnson PN, Boyles KA, Miller JL. Selection of the initial methadone regimen for the management of iatrogenic opioid abstinence syndrome in critically ill children. Pharmacotherapy. 2012;32(2):148–57. doi:10.1002/PHAR.1001.PubMed Johnson PN, Boyles KA, Miller JL. Selection of the initial methadone regimen for the management of iatrogenic opioid abstinence syndrome in critically ill children. Pharmacotherapy. 2012;32(2):148–57. doi:10.​1002/​PHAR.​1001.PubMed
51.
go back to reference Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthr Rheum. 2007;56(4):1336–44. doi:10.1002/art.22457. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthr Rheum. 2007;56(4):1336–44. doi:10.​1002/​art.​22457.
52.
go back to reference Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. Am J Manag Care. 2010;16(5 Suppl):S138–43.PubMed Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. Am J Manag Care. 2010;16(5 Suppl):S138–43.PubMed
53.
55.
go back to reference Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109–16. doi:10.1111/j.1464-5491.2010.03152.x.PubMed Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109–16. doi:10.​1111/​j.​1464-5491.​2010.​03152.​x.PubMed
56.
go back to reference Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther. 2001;23(4):520–31.PubMed Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther. 2001;23(4):520–31.PubMed
57.
go back to reference Rice AS, Maton S. Postherpetic Neuralgia Study G. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215–24.PubMed Rice AS, Maton S. Postherpetic Neuralgia Study G. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215–24.PubMed
58.
go back to reference Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837–42.PubMed Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837–42.PubMed
59.
go back to reference Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567. doi:10.1002/14651858.CD010567.pub2.PubMed Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567. doi:10.​1002/​14651858.​CD010567.​pub2.PubMed
63.
64.
go back to reference Finnerup NB, Grydehoj J, Bing J, Johannesen IL, Biering-Sorensen F, Sindrup SH, et al. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord. 2009;47(12):861–7. doi:10.1038/sc.2009.55.PubMed Finnerup NB, Grydehoj J, Bing J, Johannesen IL, Biering-Sorensen F, Sindrup SH, et al. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord. 2009;47(12):861–7. doi:10.​1038/​sc.​2009.​55.PubMed
69.
go back to reference Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611. doi:10.1002/14651858.CD010611.PubMed Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611. doi:10.​1002/​14651858.​CD010611.PubMed
70.
go back to reference Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache. 2000;40(8):672–6.PubMed Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache. 2000;40(8):672–6.PubMed
71.
go back to reference Wilder RT, Berde CB, Wolohan M, Vieyra MA, Masek BJ, Micheli LJ. Reflex sympathetic dystrophy in children. Clinical characteristics and follow-up of seventy patients. J Bone Joint Surg Am. 1992;74(6):910–9.PubMed Wilder RT, Berde CB, Wolohan M, Vieyra MA, Masek BJ, Micheli LJ. Reflex sympathetic dystrophy in children. Clinical characteristics and follow-up of seventy patients. J Bone Joint Surg Am. 1992;74(6):910–9.PubMed
72.
go back to reference Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, et al. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002;141(1):135–40. doi:10.1067/mpd.2002.124380.PubMed Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, et al. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002;141(1):135–40. doi:10.​1067/​mpd.​2002.​124380.PubMed
74.
76.
go back to reference Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76(3):287–96.PubMed Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76(3):287–96.PubMed
77.
go back to reference Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252–61. doi:10.1016/S0140-6736(09)61081-3.PubMed Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252–61. doi:10.​1016/​S0140-6736(09)61081-3.PubMed
78.
go back to reference Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1999;99(7):979–82.PubMed Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1999;99(7):979–82.PubMed
79.
go back to reference Patra KP, Sankararaman S, Jackson R, Hussain SZ. Significance of screening electrocardiogram before the initiation of amitriptyline therapy in children with functional abdominal pain. Clin Pediatr. 2012;51(9):848–51. doi:10.1177/0009922812447890. Patra KP, Sankararaman S, Jackson R, Hussain SZ. Significance of screening electrocardiogram before the initiation of amitriptyline therapy in children with functional abdominal pain. Clin Pediatr. 2012;51(9):848–51. doi:10.​1177/​0009922812447890​.
80.
go back to reference Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–8. doi:10.1038/clpt.2013.2.PubMedCentralPubMed Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–8. doi:10.​1038/​clpt.​2013.​2.PubMedCentralPubMed
84.
go back to reference Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthr Rheum. 2010;62(9):2745–56. doi:10.1002/art.27559. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthr Rheum. 2010;62(9):2745–56. doi:10.​1002/​art.​27559.
85.
go back to reference Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician. 2013;16(5):E553–62.PubMed Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician. 2013;16(5):E553–62.PubMed
87.
go back to reference Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthr Res Ther. 2013;15(4):R88. doi:10.1186/ar4268. Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthr Res Ther. 2013;15(4):R88. doi:10.​1186/​ar4268.
89.
go back to reference Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009;50(1):78–86. doi:10.1176/appi.psy.50.1.78.PubMed Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009;50(1):78–86. doi:10.​1176/​appi.​psy.​50.​1.​78.PubMed
92.
go back to reference Battistella PA, Ruffilli R, Cernetti R, Pettenazzo A, Baldin L, Bertoli S, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache. 1993;33(1):36–9.PubMed Battistella PA, Ruffilli R, Cernetti R, Pettenazzo A, Baldin L, Bertoli S, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache. 1993;33(1):36–9.PubMed
94.
go back to reference Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8):CD003460. doi:10.1002/14651858.CD003460.pub3. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8):CD003460. doi:10.​1002/​14651858.​CD003460.​pub3.
96.
97.
go back to reference Dapas F, Hartman SF, Martinez L, Northrup BE, Nussdorf RT, Silberman HM, et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo. Spine. 1985;10(4):345–9.PubMed Dapas F, Hartman SF, Martinez L, Northrup BE, Nussdorf RT, Silberman HM, et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo. Spine. 1985;10(4):345–9.PubMed
98.
go back to reference Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. J Int Med Res. 1988;16(2):83–91.PubMed Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. J Int Med Res. 1988;16(2):83–91.PubMed
99.
go back to reference Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthr Rheum. 2004;51(1):9–13. doi:10.1002/art.20076. Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthr Rheum. 2004;51(1):9–13. doi:10.​1002/​art.​20076.
103.
go back to reference Bredlau AL, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013;163(1):194 e1–200 e1. doi:10.1016/j.jpeds.2012.12.077. Bredlau AL, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013;163(1):194 e1–200 e1. doi:10.​1016/​j.​jpeds.​2012.​12.​077.
104.
107.
go back to reference Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125–8.PubMed Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125–8.PubMed
108.
go back to reference Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39(6):530–6. doi:10.1016/j.dld.2007.02.006.PubMed Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39(6):530–6. doi:10.​1016/​j.​dld.​2007.​02.​006.PubMed
110.
go back to reference Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897–905. doi:10.1177/0333102411406755.PubMed Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897–905. doi:10.​1177/​0333102411406755​.PubMed
111.
go back to reference Lodi R, Montagna P, Soriani S, Iotti S, Arnaldi C, Cortelli P, et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31P magnetic resonance spectroscopy interictal study. Pediatr Res. 1997;42(6):866–71. doi:10.1203/00006450-199712000-00024.PubMed Lodi R, Montagna P, Soriani S, Iotti S, Arnaldi C, Cortelli P, et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31P magnetic resonance spectroscopy interictal study. Pediatr Res. 1997;42(6):866–71. doi:10.​1203/​00006450-199712000-00024.PubMed
112.
go back to reference Welch KM, Ramadan NM. Mitochondria, magnesium and migraine. J Neurol Sci. 1995;134(1–2):9–14.PubMed Welch KM, Ramadan NM. Mitochondria, magnesium and migraine. J Neurol Sci. 1995;134(1–2):9–14.PubMed
113.
go back to reference Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005;25(3):199–204. doi:10.1111/j.1468-2982.2004.00840.x.PubMed Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005;25(3):199–204. doi:10.​1111/​j.​1468-2982.​2004.​00840.​x.PubMed
114.
go back to reference Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38(6):621–7. doi:10.1067/mem.2001.119424.PubMed Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38(6):621–7. doi:10.​1067/​mem.​2001.​119424.PubMed
116.
go back to reference Gallelli L, Avenoso T, Falcone D, Palleria C, Peltrone F, Esposito M, et al. Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium. Headache. 2014;54(2):313–24. doi:10.1111/head.12162.PubMed Gallelli L, Avenoso T, Falcone D, Palleria C, Peltrone F, Esposito M, et al. Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium. Headache. 2014;54(2):313–24. doi:10.​1111/​head.​12162.PubMed
117.
go back to reference Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43(6):601–10.PubMed Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43(6):601–10.PubMed
119.
go back to reference Nirschl RP, Rodin DM, Ochiai DH, Maartmann-Moe C, Group D-A-S. Iontophoretic administration of dexamethasone sodium phosphate for acute epicondylitis. A randomized, double-blinded, placebo-controlled study. Am J Sports Med. 2003;31(2):189–95. Nirschl RP, Rodin DM, Ochiai DH, Maartmann-Moe C, Group D-A-S. Iontophoretic administration of dexamethasone sodium phosphate for acute epicondylitis. A randomized, double-blinded, placebo-controlled study. Am J Sports Med. 2003;31(2):189–95.
120.
go back to reference Mina R, Melson P, Powell S, Rao M, Hinze C, Passo M, et al. Effectiveness of dexamethasone iontophoresis for temporomandibular joint involvement in juvenile idiopathic arthritis. Arthr Care Res. 2011;63(11):1511–6. doi:10.1002/acr.20600. Mina R, Melson P, Powell S, Rao M, Hinze C, Passo M, et al. Effectiveness of dexamethasone iontophoresis for temporomandibular joint involvement in juvenile idiopathic arthritis. Arthr Care Res. 2011;63(11):1511–6. doi:10.​1002/​acr.​20600.
121.
go back to reference Davies PS, Galer BS. Review of lidocaine patch 5 % studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9):937–47.PubMed Davies PS, Galer BS. Review of lidocaine patch 5 % studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9):937–47.PubMed
122.
go back to reference Orellana Silva M, Yanez V, Hidalgo G, Valenzuela F, Saavedra R. 5 % lidocaine medicated plaster use in children with neuropathic pain from burn sequelae. Pain Med. 2013;14(3):422–9. doi:10.1111/pme.12020.PubMed Orellana Silva M, Yanez V, Hidalgo G, Valenzuela F, Saavedra R. 5 % lidocaine medicated plaster use in children with neuropathic pain from burn sequelae. Pain Med. 2013;14(3):422–9. doi:10.​1111/​pme.​12020.PubMed
123.
go back to reference Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5 %. Am J Health Syst Pharm. 2002;59(22):2215–20.PubMed Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5 %. Am J Health Syst Pharm. 2002;59(22):2215–20.PubMed
127.
go back to reference Lauretti GR. Mechanisms of analgesia of intravenous lidocaine. Revista Bras Anestesiol. 2008;58(3):280–6. Lauretti GR. Mechanisms of analgesia of intravenous lidocaine. Revista Bras Anestesiol. 2008;58(3):280–6.
128.
go back to reference Mooney JJ, Pagel PS, Kundu A. Safety, tolerability, and short-term efficacy of intravenous lidocaine infusions for the treatment of chronic pain in adolescents and young adults: a preliminary report. Pain Med. 2014. doi:10.1111/pme.12333.PubMed Mooney JJ, Pagel PS, Kundu A. Safety, tolerability, and short-term efficacy of intravenous lidocaine infusions for the treatment of chronic pain in adolescents and young adults: a preliminary report. Pain Med. 2014. doi:10.​1111/​pme.​12333.PubMed
129.
go back to reference Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005;115(4):e504–7. doi:10.1542/peds.2004-1395.PubMed Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005;115(4):e504–7. doi:10.​1542/​peds.​2004-1395.PubMed
130.
131.
go back to reference Yaster M, Tobin JR, Billett C, Casella JF, Dover G. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis. Pediatrics. 1994;93(2):310–5.PubMed Yaster M, Tobin JR, Billett C, Casella JF, Dover G. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis. Pediatrics. 1994;93(2):310–5.PubMed
135.
go back to reference Kosharskyy B, Almonte W, Shaparin N, Pappagallo M, Smith H. Intravenous infusions in chronic pain management. Pain Physician. 2013;16(3):231–49.PubMed Kosharskyy B, Almonte W, Shaparin N, Pappagallo M, Smith H. Intravenous infusions in chronic pain management. Pain Physician. 2013;16(3):231–49.PubMed
136.
go back to reference Eckmann MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocaine in the treatment of complex regional pain syndrome of the lower extremity: a randomized, double-blinded, crossover study. Clin J Pain. 2011;27(3):203–6. doi:10.1097/AJP.0b013e3181fd5150.PubMed Eckmann MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocaine in the treatment of complex regional pain syndrome of the lower extremity: a randomized, double-blinded, crossover study. Clin J Pain. 2011;27(3):203–6. doi:10.​1097/​AJP.​0b013e3181fd5150​.PubMed
137.
go back to reference Suresh S, Wheeler M, Patel A. Case series: IV regional anesthesia with ketorolac and lidocaine: is it effective for the management of complex regional pain syndrome 1 in children and adolescents? Anesth Analg. 2003;96(3):694–5 (table of contents)PubMed Suresh S, Wheeler M, Patel A. Case series: IV regional anesthesia with ketorolac and lidocaine: is it effective for the management of complex regional pain syndrome 1 in children and adolescents? Anesth Analg. 2003;96(3):694–5 (table of contents)PubMed
138.
go back to reference Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35(2):65–9.PubMed Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35(2):65–9.PubMed
139.
142.
go back to reference Shaddy RE, Denne SC. Committee on D, Committee on Pediatric R. Clinical report–guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 2010;125(4):850–60. doi:10.1542/peds.2010-0082.PubMed Shaddy RE, Denne SC. Committee on D, Committee on Pediatric R. Clinical report–guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 2010;125(4):850–60. doi:10.​1542/​peds.​2010-0082.PubMed
143.
go back to reference McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. The journal of pain: official journal of the American Pain Society. 2008;9(9):771–83. doi:10.1016/j.jpain.2008.04.007. McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. The journal of pain: official journal of the American Pain Society. 2008;9(9):771–83. doi:10.​1016/​j.​jpain.​2008.​04.​007.
Metadata
Title
Pharmacological Treatment of Chronic Non-Cancer Pain in Pediatric Patients
Authors
Eapen Mathew
Eugene Kim
Kenneth R. Goldschneider
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2014
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-014-0092-2

Other articles of this Issue 6/2014

Pediatric Drugs 6/2014 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees